# BlossomHill Therapeutics Inc. (BLSM) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $12.41, market value $394 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). BlossomHill Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -12.2%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 46.0%**. 46.0% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): -150.5%**. Earnings per share fell 150.5%.

## Financial health
- **Current ratio: 8.97** (quick 8.97). Current assets cover the next year's liabilities 8.97 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. BlossomHill Therapeutics Inc. does not currently pay a dividend, but it returned -21.3% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover BlossomHill Therapeutics Inc.; the consensus is strong_buy, with an average price target of $35.40 (+185% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -55.7%** (1.1% above the low). Trading 56% below its 52-week high, deep in a drawdown.
- **RSI (14-day): 34**. An RSI of 34 is neutral.

Live score and charts: https://foliofundamentals.com/analyzer?s=BLSM · Page: https://foliofundamentals.com/stocks/blsm

Not investment advice.